Corti
cotropi
n-releasi
ng fa
ctor (CRF) is impli
cated i
n the pathoge
nesis of bipolar disorder, a
n ill
ness asso
ciated with defi
cits i
n prepulse i
nhibitio
n (PPI) of the a
cousti
c startle respo
nse. Valproate is used i
n the treatme
nt of bipolar disorder a
nd may alter CRF a
ctivity via a GABA
A-ergi
c me
cha
nism. This study determi
ned the effe
ct of valproate o
n CRF-disrupted PPI a
nd exami
ned the role of the hypothalami
c-pituitary-adre
nal axis a
nd GABA-ergi
c sig
nali
ng i
n the effe
ct of valproate. Valproate (60-240聽mg/kg) dose-depe
nde
ntly reversed PPI defi
cits displayed by tra
nsge
ni
c mi
ce overexpressi
ng CRF (CRFtg), a
nd
normalized PPI defi
cits i
ndu
ced by CRF i.
c.v. i
nfusio
n i
n 129Sv mi
ce. Valproate e
nha
nced
corti
costero
ne se
cretio
n more effe
ctively i
n CRFtg tha
n i
n wild-type mi
ce. The effe
ct of valproate o
n PPI was
not blo
cked by the GABA
A re
ceptor a
ntago
nist bi
cu
culli
ne, the GABA
B re
ceptor a
ntago
nists pha
clofe
n a
nd SCH 50911 or
combi
ned admi
nistratio
n of a GABA
A a
nd GABA
B re
ceptor a
ntago
nist. The be
nefi
cial effe
ct of valproate o
n PPI was
not mimi
cked by the GABA
A re
ceptor ago
nist mus
cimol, the GABA tra
nsami
nase i
nhibitor vigabatri
n, the histo
ne dea
cetylase (HDAC) i
nhibitor sodium butyrate or by the mood stabilizers lithium,
carbamazepi
ne, lamotrigi
ne or topiramate.
Thus, we showed that valproate improves CRF-induced PPI deficits, albeit via a so far unknown mechanism. These marked beneficial effects of valproate on CRF-induced sensorimotor gating deficits suggest that valproate may be of particular value in specific subgroups of bipolar patients that are characterized by alterations in the CRF system.